Micaela Morelli
#157,526
Most Influential Person Now
Researcher, ORCID id # 0000-0003-0394-5782
Micaela Morelli's AcademicInfluence.com Rankings
Micaela Morellicomputer-science Degrees
Computer Science
#8766
World Rank
#9217
Historical Rank
Computational Linguistics
#2013
World Rank
#2035
Historical Rank
Machine Learning
#3677
World Rank
#3723
Historical Rank
Artificial Intelligence
#3989
World Rank
#4047
Historical Rank
Download Badge
Computer Science
Micaela Morelli's Degrees
- Masters Artificial Intelligence Stanford University
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Micaela Morelli Influential?
(Suggest an Edit or Addition)Micaela Morelli's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Adenosine–dopamine receptor–receptor interactions as an integrative mechanism in the basal ganglia (1997) (802)
- Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions (1994) (470)
- Targeting adenosine A2A receptors in Parkinson's disease (2006) (430)
- Evidence for a gabaergic projection from the substantia nigra to the ventromedial thalamus and to the superior colliculus of the rat (1979) (393)
- Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease (2015) (346)
- The 6-Hydroxydopamine model of parkinson’s disease (2007) (337)
- Caffeine and the dopaminergic system (2005) (175)
- Adenosine, adenosine A 2A antagonists, and Parkinson's disease. (2009) (173)
- [3H]Ro5-4864 benzodiazepine binding in the kainate lesioned striatum and Huntington's diseased basal ganglia (1982) (162)
- Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms (2017) (160)
- Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. (1997) (156)
- Catalepsy induced by SCH 23390 in rats. (1985) (152)
- Blockade of A2a Adenosine Receptors Positively Modulates Turning Behaviour and c‐Fos Expression Induced by D1 Agonists in Dopamine‐denervated Rats (1996) (148)
- Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications (2007) (139)
- Adenosine A2A receptors and Parkinson's disease. (2009) (134)
- Opposite effects of NMDA receptor blockade on dopaminergic D1- and D2-mediated behavior in the 6-hydroxydopamine model of turning: relationship with c-fos expression. (1992) (130)
- Chapter I The organization and circuits of mesencephalic dopaminergic neurons and the distribution of dopamine receptors in the brain (2005) (118)
- Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6‐hydroxydopamine‐lesioned rats (2001) (112)
- Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats. (1994) (105)
- MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease. (1990) (103)
- Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: Comparison of the effects of different psychoactive drugs and relevance in drug-induced reward (2012) (99)
- Pathophysiological roles for purines: adenosine, caffeine and urate. (2010) (97)
- Time and dose dependence of the 'priming' of the expression of dopamine receptor supersensitivity. (1989) (96)
- Gut Microbiota and Metabolome Alterations Associated with Parkinson’s Disease (2020) (94)
- New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. (2005) (94)
- Role of thalamic γ-aminobutyrate in motor functions: Catalepsy and ipsiversive turning after intrathalamic muscimol (1979) (91)
- Agonist-induced homologous and heterologous sensitization to D-1- and D-2-dependent contraversive turning. (1987) (90)
- Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions (2004) (88)
- Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation. (2002) (86)
- Birth asphyxia as the major complication in newborns: moving towards improved individual outcomes by prediction, targeted prevention and tailored medical care (2011) (85)
- Evidence that nigral GABA mediates behavioural responses elicited by striatal dopamine receptor stimulation. (1978) (84)
- Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6‐hydroxydopamine rat model of Parkinson's disease (2007) (82)
- Quantitative autoradiographical analysis of the age-related modulation of central dopamine D1 and D2 receptors (1990) (82)
- Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. (2007) (82)
- Assessment of Symptomatic and Neuroprotective Efficacy of Mucuna Pruriens Seed Extract in Rodent Model of Parkinson’s Disease (2009) (80)
- Different responsiveness of striatonigral and striatopallidal neurons to L‐DOPA after a subchronic intermittent L‐DOPA treatment (2005) (73)
- Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions. (2008) (73)
- The Basal Ganglia III (1991) (68)
- Adenosine A2 receptors stimulate c-fos expression in striatal neurons of 6-hydroxydopamine-lesioned rats (1995) (68)
- A re-evaluation of the role of superior colliculus in turning behaviour (1982) (67)
- Inactivation of neuronal forebrain A2A receptors protects dopaminergic neurons in a mouse model of Parkinson’s disease (2009) (67)
- Involvement of Adenosine A2A Receptors in the Induction of C-Fos Expression by Clozapine and Haloperidol (1999) (67)
- Dyskinesia in Parkinson's disease: mechanisms and current non‐pharmacological interventions (2014) (67)
- Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis. (2008) (65)
- Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease (2001) (65)
- Benzodiazepine receptor binding in young, mature and senescent rat brain and kidney (1981) (64)
- Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic‐intermittent L‐dopa and A2A receptor blockade plus L‐Dopa in dopamine‐denervated rats (2002) (63)
- Late-onset Parkinsonism in NFκB/c-Rel-deficient mice (2012) (63)
- Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties. (2003) (60)
- Adenosine A2A receptor agonists increase Fos-like immunoreactivity in mesolimbic areas (1997) (60)
- Effect of discrete kainic acid-induced lesions of corpus caudatus and globus pallidus on glutamic acid decar☐ylase of rat substantia nigra (1980) (58)
- Direct and long-lasting effects elicited by repeated drug administration on 50-kHz ultrasonic vocalizations are regulated differently: implications for the study of the affective properties of drugs of abuse. (2014) (58)
- Induction of fos‐like‐immunoreactivity in the central extended amygdala by antidepressant drugs (1999) (57)
- Perinatal asphyxia: current status and approaches towards neuroprotective strategies, with focus on sentinel proteins (2010) (54)
- Caffeine Enhances Astroglia and Microglia Reactivity Induced by 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) in Mouse Brain (2010) (53)
- Expression of c‐fos protein in the experimental epilepsy induced by pilocarpine (1993) (52)
- l-Dopa stimulates c-fos expression in dopamine denervated striatum by combined activation of D-1 and D-2 receptors (1993) (51)
- Subchronic Caffeine Exposure Induces Sensitization to Caffeine and Cross-Sensitization to Amphetamine Ipsilateral Turning Behavior Independent from Dopamine Release (2003) (51)
- Acute perinatal asphyxia impairs non-spatial memory and alters motor coordination in adult male rats (2008) (51)
- Substantia nigra as a site of origin of dopamine-dependent motor syndromes induced by stimulation of μ and δ opioid receptors (1989) (50)
- Nigral dopamine autoreceptors are exclusively of the D2 type: Quantitative autoradiography of [125I]iodosulpride and [125I]SCH 23982 in adjacent brain sections (1988) (50)
- Blockade of muscarinic receptors potentiates D1 dependent turning behavior and c-fos expression in 6-hydroxydopamine-lesioned rats but does not influence D2 mediated responses (1993) (50)
- Adenosine A2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats. (2003) (49)
- Role of Neuroactive Steroid Allopregnanolone in Antipsychotic-like Action of Olanzapine in Rodents (2004) (49)
- Vitamin A deficiency induces motor impairments and striatal cholinergic dysfunction in rats (2006) (47)
- Behavioural expression of D-1 receptor supersensitivity depends on previous stimulation of D-2 receptors. (1987) (47)
- Novel Inhibitors of Rad6 Ubiquitin Conjugating Enzyme: Design, Synthesis, Identification, and Functional Characterization (2013) (46)
- MPTP‐induced dopamine neuron degeneration and glia activation is potentiated in MDMA‐pretreated mice (2013) (46)
- Lesions of substantia nigra by kainic acid: Effects on apomorphine-induced stereotyped behaviour (1980) (46)
- Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease (2016) (46)
- Role of dorsal mesencephalic reticular formation and deep layers of superior colliculus as out-put stations for turning behaviour elicited from the substantia nigra pars reticulata (1981) (45)
- Motor stimulant effects of caffeine in 6‐hydroxydopamine‐lesioned rats are dependent on previous stimulation of dopamine receptors: a different role of D1 and D2 receptors (1998) (45)
- New adenosine A2A receptor antagonists: actions on Parkinson's disease models. (2005) (45)
- Expression of dyskinetic movements and turning behaviour in subchronic l-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment (2006) (44)
- Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6‐hydroxydopamine‐lesioned rats (2003) (44)
- A new ethyladenine antagonist of adenosine A2A receptors: Behavioral and biochemical characterization as an antiparkinsonian drug (2010) (44)
- Microglial and astroglial activation by 3,4‐methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility (2013) (43)
- Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease (2009) (43)
- Role of dorsal mesencephalic reticular formation and deep layers of superior colliculus in turning behaviour elicited from the striatum (1981) (42)
- Nicotinamide prevents the long-term effects of perinatal asphyxia on apoptosis, non-spatial working memory and anxiety in rats (2010) (40)
- MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex (2014) (40)
- Non-dopaminergic mechanisms in the turning behavior evoked by intranigral opiates (1985) (38)
- Involvement of Glutamate NMDA Receptors in the Acute, Long-Term, and Conditioned Effects of Amphetamine on Rat 50kHz Ultrasonic Vocalizations (2015) (37)
- Sensitization to caffeine and cross-sensitization to amphetamine: Influence of individual response to caffeine (2006) (37)
- Behavioural sensitization in 6-hydroxydopamine lesioned rats involves the dopamine signal transduction: Changes in DARPP-32 phosphorylation (1994) (36)
- Repeated amphetamine administration and long-term effects on 50-kHz ultrasonic vocalizations: Possible relevance to the motivational and dopamine-stimulating properties of the drug (2015) (36)
- Anxiolytic properties of a 2-phenylindolglyoxylamide TSPO ligand: Stimulation of in vitro neurosteroid production affecting GABAA receptor activity (2011) (36)
- Behavioural sensitization in 6-hydroxydopamine-lesioned rats is related to compositional changes of the AP-1 transcription factor: evidence for induction of FosB- and JunD-related proteins. (1997) (35)
- Role of GABA neurons in the expression of striatal motor functions. (1981) (34)
- [3H]CL 218,872, a novel triazolopyridazine which labels the benzodiazepine receptors in rat brain. (1982) (34)
- Attention-Deficit and Disruptive Behavior Disorders (2014) (33)
- Dopamine-acetylcholine-glutamate interactions in the striatum. A working hypothesis. (1993) (32)
- Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease (2016) (32)
- Subchronic caffeine administration sensitizes rats to the motor-activating effects of dopamine D1 and D2 receptor agonists (2002) (31)
- "Priming" to dopamine agonist-induced contralateral turning as a model of non-associative sensitization to the expression of the post-synaptic dopamine message. (1993) (31)
- Local cerebral glucose utilization after D1 receptor stimulation in 6‐OHDA lesioned rats: Effect of sensitization (priming) with a dopaminergic agonist (1993) (31)
- Functions of dopamine in the extrapyramidal and limbic systems. Clues for the mechanism of drug actions. (1992) (30)
- EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson’s disease (2003) (30)
- Neuroprotective and anti‐inflammatory effects of the adenosine A2A receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease (2011) (29)
- D1-Receptor-related priming is attenuated by antisense-meditated 'knockdown' of fosB expression. (1998) (29)
- Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease (2014) (29)
- Role of substantia nigra pars reticulata neurons in the expression of neuroleptic-induced catalepsy (1981) (29)
- Role of adenosine A2A receptors in motor control: relevance to Parkinson’s disease and dyskinesia (2018) (28)
- Changes in the D1 receptor-adenylate cyclase complex after priming. (1990) (28)
- Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease (2006) (28)
- Biomarkers for prediction and targeted prevention of Alzheimer’s and Parkinson’s diseases: evaluation of drug clinical efficacy (2010) (28)
- Stimulation of dopamine transmission in the dorsal caudate nucleus by pargyline as demonstrated by dopamine and acetylcholine microdialysis and Fos immunohistochemistry (1993) (27)
- Alterations in GAD67, dynorphin and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson's disease (2001) (26)
- 6-Hydroxydopamine lesions reduce specific [3H]sulpiride binding in the rat substantia nigra: direct evidence for the existence of nigral D-2 autoreceptors. (1987) (26)
- How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease? (2006) (26)
- Differential effect of MK 801 and scopolamine on c‐fos expression induced by L‐dopa in the striatum of 6‐hydroxydopamine lesioned rats (1994) (26)
- Cross-sensitization between the motor activating effects of bromocriptine and caffeine: role of adenosine A2A receptors (2000) (26)
- Blockade of A2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata (2003) (25)
- Methylxanthines and drug dependence: a focus on interactions with substances of abuse. (2011) (25)
- Priming of 6-hydroxydopamine-lesioned rats with L-DOPA or quinpirole results in an increase in dopamine D1 receptor-dependent cyclic AMP production in striatal tissue. (1997) (25)
- Mitochondrial Homeostasis and Signaling in Parkinson’s Disease (2020) (24)
- Synthesis of new 2-arylamino-6-trifluoromethylpyridine-3-carboxylic acid derivatives and investigation of their analgesic activity. (2004) (24)
- Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization. (2012) (24)
- Clinical Phenotypes of Parkinson’s Disease Associate with Distinct Gut Microbiota and Metabolome Enterotypes (2021) (24)
- Increase of dopamine D2High receptors in the striatum of rats sensitized to caffeine motor effects (2008) (24)
- Metformin Prevented Dopaminergic Neurotoxicity Induced by 3,4-Methylenedioxymethamphetamine Administration (2016) (23)
- Progression and Persistence of Neurotoxicity Induced by MDMA in Dopaminergic Regions of the Mouse Brain and Association with Noradrenergic, GABAergic, and Serotonergic Damage (2017) (23)
- Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats (2003) (23)
- Activation of adenosine A2A receptors suppresses the emission of pro-social and drug-stimulated 50-kHz ultrasonic vocalizations in rats: possible relevance to reward and motivation (2016) (22)
- Influence of caffeine on 3,4‐methylenedioxymethamphetamine‐induced dopaminergic neuron degeneration and neuroinflammation is age‐dependent (2016) (22)
- Adenosine A2A receptor antagonists: Potential therapeutic and neuroprotective effects in parkinson’s disease (2001) (22)
- Potentiation of amphetamine‐mediated responses in caffeine‐sensitized rats involves modifications in A2A receptors and zif‐268 mRNAs in striatal neurons (2006) (22)
- A Critical Evaluation of Behavioral Rodent Models of Motor Impairment Used for Screening of Antiparkinsonian Activity: The Case of Adenosine A2A Receptor Antagonists (2014) (22)
- NCX1 and NCX3 as potential factors contributing to neurodegeneration and neuroinflammation in the A53T transgenic mouse model of Parkinson’s Disease (2018) (21)
- 6‐n‐propylthiouracil taste disruption and TAS2R38 nontasting form in Parkinson's disease (2018) (21)
- Combined Microdialysis and Fos Immunohistochemistry for the Estimation of Dopamine Neurotransmission in the Rat Caudate‐Putamen (1992) (21)
- Neurochemical and Neurotoxic Effects of MDMA (Ecstasy) and Caffeine After Chronic Combined Administration in Mice (2017) (21)
- Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer’s and Parkinson’s diseases (2011) (21)
- Differential Induction of Fos-Like-Immunoreactivity in the Extended Amygdala after Haloperidol and Clozapine (1999) (21)
- Neuropharmacology of the adenosine A2A receptors (1996) (20)
- Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence. (2008) (20)
- Adenosine A2A antagonists: potential preventive and palliative treatment for Parkinson's disease (2003) (20)
- The effect of temperature on CL 218872 and propyl beta-carboline-3-carboxylate inhibition of [3H]-flunitrazepam binding in rat brain. (1982) (20)
- Destruction of post-synaptic dopamine receptors prevents neuroleptic-induced activation of striatal tyrosine hydroxylase but not dopamine synthesis stimulation. (1978) (19)
- Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons (2013) (19)
- Odor Identification Performance in Idiopathic Parkinson's Disease Is Associated With Gender and the Genetic Variability of the Olfactory Binding Protein. (2019) (19)
- Genetic variants of TAS2R38 bitter taste receptor associate with distinct gut microbiota traits in Parkinson's disease: A pilot study. (2020) (19)
- Metabolic mapping of the pharmacological and toxicological effects of dopaminergic drugs in experimental animals. (1993) (19)
- Lack of Rhes Increases MDMA-Induced Neuroinflammation and Dopamine Neuron Degeneration: Role of Gender and Age (2019) (19)
- Blockade of N-methyl-D-aspartate receptors potentiates dopaminergic responses in the 6-OHDA model of parkinson: Differential role of D-1 and D-2 receptors (1992) (19)
- Effect of MK 801 on priming of D1-dependent contralateral turning and its relationship to c-fos expression in the rat caudate-putamen (1996) (19)
- Substantia nigra as an out-put station for striatal dopaminergic responses: Role of a GABA-mediated inhibition of pars reticulata neurons (1979) (18)
- Increased striatal expression of glutamate decarboxylase 67 after priming of 6-hydroxydopamine-lesioned rats (1999) (18)
- Antagonism of apomorphine-induced yawning by SCH 23390: Evidence against the autoreceptor hypothesis (2004) (18)
- Opposite turning effects of kainic and ibotenic acid injected in the rat substantia nigra (1979) (18)
- Loss of striatal neurons after local microinjection of colchicine (1980) (17)
- Autoradiographic localization of [3H] [MePhe3,D-Pro4]morphiceptin ([3H]PL017) to mu opioid receptors in rat brain. (1987) (17)
- Involvement of globus pallidus in the antiparkinsonian effects of adenosine A2A receptor antagonists (2006) (17)
- Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression (2010) (17)
- Modulation of dopamine D1‐mediated turning behavior and striatal c‐fos expression by the substantia nigra (1995) (17)
- The effect of GABA on in vitro binding of two novel non-benzodiazepines, PK 8165 and CGS 8216, to benzodiazepine receptors in the rat brain. (1982) (17)
- Priming as a model of behavioural sensitization. (1992) (17)
- Rehabilitation improves dyskinesias in Parkinsonian patients: a pilot study comparing two different rehabilitative treatments. (2012) (17)
- Modulation of Rat 50-kHz Ultrasonic Vocalizations by Glucocorticoid Signaling: Possible Relevance to Reward and Motivation (2017) (16)
- Priming of rotational behavior by a dopamine receptor agonist in hemiparkinsonian rats: Movement-dependent induction (2009) (16)
- Multiple mechanisms of neurodegeneration and progression (2017) (16)
- Output Pathways Mediating Basal Ganglia Function (1984) (16)
- Antidepressants and Atypical Neuroleptics Induce Fos‐like Immunoreactivity in the Central Extended Amygdala (1999) (16)
- Motor stimulant effects of the adenosine A(2A) receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. (2001) (15)
- A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L‐DOPA‐induced dyskinesia in Parkinson's disease (2017) (15)
- Modulation of GABA-stimulated chloride influx into membrane vesicles from rat cerebral cortex by benzodiazepines and nonbenzodiazepines. (1988) (15)
- A2A Receptor Antagonism and Dyskinesia in Parkinson's Disease (2012) (15)
- Adenosine A(2a) receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease. (2001) (15)
- Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa‐carbidopa intrajejunal gel (2020) (14)
- Effect of crowding, temperature and age on glia activation and dopaminergic neurotoxicity induced by MDMA in the mouse brain. (2016) (14)
- Decreased Rhes mRNA levels in the brain of patients with Parkinson’s disease and MPTP-treated macaques (2017) (14)
- Subchronic-intermittent caffeine amplifies the motor effects of amphetamine in rats (2006) (14)
- The Small GTP‐Binding Protein Rhes Influences Nigrostriatal‐Dependent Motor Behavior During Aging (2016) (13)
- Benzodiazepines prevent kainate-induced loss of GABAergic and cholinergic neurons in the chick retina (1981) (13)
- Behavioral, Neurochemical, and Electrophysiological Changes in an Early Spontaneous Mouse Model of Nigrostriatal Degeneration (2011) (13)
- Positive and negative interactions in the behavioural expression of d1 and D2 receptor stimulation in a model of parkinsonism: Role of priming (1991) (13)
- Stereospecific blockade of N-methyl-d-aspartate transmission by MK 801 prevents priming of SKF 38393-induced turning (2005) (12)
- Influence of dopamine transmission in the medial prefrontal cortex and dorsal striatum on the emission of 50-kHz ultrasonic vocalizations in rats treated with amphetamine: Effects on drug-stimulated and conditioned calls (2020) (12)
- Intensive Rehabilitation Treatment in Parkinsonian Patients with Dyskinesias: A Preliminary Study with 6-Month Followup (2012) (12)
- Dopamine/glutamate interaction as studied by combining turning behaviour and c-Fos expression (1997) (12)
- Gender Differences in Neurodegeneration, Neuroinflammation and Na+-Ca2+ Exchangers in the Female A53T Transgenic Mouse Model of Parkinson’s Disease (2020) (12)
- Adenosine in the central nervous system: Effects on neurotransmission and neuroprotection. (2007) (12)
- Blockade of globus pallidus adenosine A2A receptors displays antiparkinsonian activity in 6‐hydroxydopamine‐lesioned rats treated with D1 or D2 dopamine receptor agonists (2008) (11)
- Substantia nigra as a site of origin of dopamine-dependent motor syndromes induced by stimulation of mu and delta opioid receptors. (1989) (11)
- Allosteric modulators for adenosine receptors: an alternative to the orthosteric ligands. (2010) (10)
- Effect of barbiturates and benzodiazepines on local kainate toxicity in the striatum and in the retina. (1981) (10)
- Synthesis of substituted carbamo(dithioperoxo)thioates as potential BCA2-inhibitory anticancer agents (2015) (9)
- Alteration in the progression of dopamine neuron degeneration: May caffeine offer new perspective? (2012) (9)
- Optimised synthesis of diamino-triazinylmethyl benzoates as inhibitors of Rad6B ubiquitin conjugating enzyme (2014) (9)
- Coexistence of GABA and enkephalin striatal neurons and possible coupling of GABA-ergic and opiatergic systems in the basal ganglia (1984) (9)
- Elevation of striatal urate in experimental models of Parkinson's disease: a compensatory mechanism triggered by dopaminergic nigrostriatal degeneration? (2014) (9)
- Subchronic intermittent caffeine administration to unilaterally 6-hydroxydopamine-lesioned rats sensitizes turning behaviour in response to dopamine D1 but not D2 receptor agonists (2005) (8)
- Receptor tyrosine kinase kit and gastrointestinal stromal tumours: an overview. (2011) (8)
- Rhes Counteracts Dopamine Neuron Degeneration and Neuroinflammation Depending on Gender and Age (2018) (8)
- Repeated Administration of 3,4-Methylenedioxymethamphetamine (MDMA) Elevates the Levels of Neuronal Nitric Oxide Synthase in the Nigrostriatal System: Possible Relevance to Neurotoxicity (2018) (8)
- Metabolic mapping of the synergism between MK‐801 and SKF 38393 in rats with unilateral lesions of the dopaminergic nigrostriatal pathway (1992) (8)
- Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT1A/1B receptor agonist and A2A receptor antagonist (2021) (8)
- Dopamine — Adenosine Interactions (2002) (7)
- Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease (2013) (6)
- Acetylcholine, Dopamine and NMDA Transmission in the Caudate-Putamen: Their Interaction and Function as a Striatal Modulatory System (1994) (6)
- Localization of MPP+ binding sites in the brain of various mammalian species (1992) (6)
- Contribution of Caffeine to the Psychostimulant, Neuroinflammatory and Neurotoxic Effects of Amphetamine-Related Drugs (2013) (6)
- C‐Fos expression as a molecular marker in corticotropin‐releasing factor‐induced seizures (1996) (6)
- Increased emissions of 50-kHz ultrasonic vocalizations in hemiparkinsonian rats repeatedly treated with dopaminomimetic drugs: A potential preclinical model for studying the affective properties of dopamine replacement therapy in Parkinson's disease (2020) (6)
- PRIMING TO DOPAMINE AGONISTS IN THE 6-HYDROXYDOPAMINE MODEL OF TURNING AS A MODEL OF NON-ASSOCIATIVE SENSITIZATION (1993) (5)
- Role of dopamine receptors in the induction and expression of rotational behavior induced by caffeine in 6‐hydroxydopamine‐lesioned rats (1998) (5)
- Dopamine mediated responses in 6-hydroxydopamine lesioned rats involve changes of the signal transduction. (1995) (4)
- S.23.02 Interaction between caffeine and the dopaminergic system (2004) (4)
- Involvement of the Protein Ras Homolog Enriched in the Striatum, Rhes, in Dopaminergic Neurons’ Degeneration: Link to Parkinson’s Disease (2021) (4)
- Role of movement in long-term basal ganglia changes: implications for abnormal motor responses (2013) (4)
- Brief history of the medical and non-medical use of amphetamine-like psychostimulants (2021) (4)
- Ethanol: lack of stimulation of chloride influì in rat brain synaptoneurosomes (1988) (4)
- Intranigral injections of glutamate antagonists modulate dopamine D1-mediated turning behavior and striatal c-fos expression. (1995) (3)
- Pharmacological interactions between adenosine A2A receptor antagonists and different neurotransmitter systems. (2020) (3)
- In utero exposure to dexamethasone causes a persistent and age-dependent exacerbation of the neurotoxic effects and glia activation induced by MDMA in dopaminergic brain regions of C57BL6/J mice. (2020) (3)
- Activation of Antioxidant and Proteolytic Pathways in the Nigrostriatal Dopaminergic System After 3,4-Methylenedioxymethamphetamine Administration: Sex-Related Differences (2021) (3)
- Effect of MK 801 on priming of D-1-dependent contralateral turning and its relationship to c-fos expression in the rat caudate-putamen (1995) (3)
- A 2 A Receptor Antagonism and Dyskinesia in Parkinson ’ s Disease (2014) (3)
- Fos expression induced by olanzapine and risperidone in the central extended amygdala. (2019) (3)
- Methylxanthines and drug dependence: interactions and toxicity (2016) (3)
- Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists (2014) (3)
- Immunohistochemical localization of Leu-enkephalin and glutamic acid decarboxylase in the nucleus caudatus of the rat (1983) (3)
- Blockade of NMDA transmission potentiates dopaminergic D-1 while reduces D-2 responses in the 6-OHDA model of parkinson (1990) (2)
- Origin of GABA-ergic strio-nigral neurons as studied by kainate-induced lesions. (1980) (2)
- Antagonism of Adenosine A1 or A2A Receptors Amplifies the Effects of 3,4-Methylendioxymethamphetamine (MDMA) on Glial Activation in the Mouse Brain: Relevance to Caffeine-MDMA Interactions (2014) (2)
- Modulation by adenosine A2A receptors of dopamine‐mediated motor behavior as a basis for antiparkinson’s disease drugs (2001) (2)
- Affective State (2020) (2)
- P.2.045 Involvement of adenosine A2A receptors in the induction of c-fos expression by clozapine (1997) (2)
- Characterization of Nasco grape pomace-loaded nutriosomes and their neuroprotective effects in the MPTP mouse model of Parkinson’s disease (2022) (2)
- Can dietary substances protect against Parkinson's disease? The case of caffeine (2010) (2)
- ADENOSINE A2A RECEPTOR AGONISTS INCREASE Fos‐LIKE IMMUNOREACTIVITY PREFERENTIALLY IN THE LIMBIC SYSTEM: SIMILARITIES WITH ATYPICAL ANTIPSYCHOTICS (1998) (2)
- What do you see as the main priorities, Opportunities, and Challenges in Caffeine Research in the Next Five Years? (2011) (2)
- CAFFEINE SESITIZATION AND CROSS-SENSITIZATION WITH AMPHETAMINE: ASSOCIATION TO POST-SYNAPTIC CHANGES IN RAT STRIATAL NEURONS (2005) (1)
- Why is fake news so fascinating to the brain? (2022) (1)
- Self-inhibitory dopamine-receptors and central effects of apomorphine. (1978) (1)
- Geometrically constrained derivatives of indolylglyoxylamides as ligands binding the GABAA/BzR complex. (2012) (1)
- Excitatory Amino Acids and Their Antagonists (2015) (1)
- Role of Adenosine in the Basal Ganglia (2010) (1)
- Adenosine A2A Receptor Antagonists in L-DOPA-Induced Motor Fluctuations (2015) (1)
- Erratum to: MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex (2014) (1)
- Dihydroergotoxine potentiation of thioridazine-induced hypomotility. (1986) (1)
- Involvement of the Protein Ras Homolog Enriched in the Striatum, Rhes, in Dopaminergic Neurons Degeneration: Link to Parkison’s Disease (2021) (1)
- Attention Deficit Hyperactivity Disorders: Animal Models (2014) (1)
- Irreversible neuronal damage after intrastriatal injection of colchicine. (1980) (1)
- P2.106 Assessment of symptomatic and neuroprotective efflcacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease (2009) (1)
- Involvement of adenosine A2A receptors in the c-Fos expression induced by clozapine and haloperidol (1998) (1)
- Protective Agents in Parkinson’s Disease: Caffeine and Adenosine A2A Receptor Antagonists (2021) (1)
- Prediction and targeted prevention of Parkinson's and Alzheimer's diseases (2009) (1)
- Control of Motor Function by Adenosine A2A Receptors in Parkinson's and Huntington's Disease (2017) (1)
- Effects of docosanyl ferulate, a constituent of Withania somnifera, on ethanol- and morphine-elicited conditioned place preference and ERK phosphorylation in the accumbens shell of CD1 mice (2022) (1)
- Stimulation of adenosine A2 receptors induces c-fos expression in striatum of dopamine denervated rats (1995) (0)
- Caffeine consumption and changes in the function of dopaminergic transmission: evidence of a hyperdopaminergic state in rats subchronically treated with caffeine (2009) (0)
- Bezaed review dyskinesia 2015 progr neurobiol (2015) (0)
- PREFRONTAL CORTEX, CAUDATE NUCLEUS AND COGNITION IN MONKEYS: RELEVANCE TO PARKINSON??S AND HUNTINGTON??S DISEASES (1996) (0)
- “Priming” of the expression of dopamine D-1 receptor supersensitivity: Beavioural and neurochemical studies (1988) (0)
- Comics and studies on brain functions (2018) (0)
- Effect of caffeine on 3,4- methylenedioxymethamphetamine-induced neuroinflammation in mouse brain (2009) (0)
- Chapter 11 – Role of Adenosine in the Basal Ganglia (2010) (0)
- D2R signaling in striatal spiny neurons modulates L-DOPA induced dyskinesia (2022) (0)
- Withania somnifera influences MDMA-induced hyperthermic, cognitive, neurotoxic and neuroinflammatory effects in mice. (2023) (0)
- Caffeine intoxication (2015) (0)
- Editorial Board (2007) (0)
- MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex (2014) (0)
- Efficacy (2021) (0)
- Blockade of nitric-oxide synthase prevents priming to dopamine D1 receptors in dopamine denervated rats: 15.4 (1995) (0)
- Carbidopa (2020) (0)
- Encoding (2021) (0)
- Contents page,Editorial Board (2006) (0)
- Activities of Daily Living (2021) (0)
- Repeated Administration of 3,4-Methylenedioxymethamphetamine (MDMA) Elevates the Levels of Neuronal Nitric Oxide Synthase in the Nigrostriatal System: Possible Relevance to Neurotoxicity (2018) (0)
- Dopamine mediated responses in 6-OH-DA lesioned rats involve changes of the signal transduction. (1995) (0)
- Effect of adenosine A1 and A2A antagonists on 3,4 methylenedioxymethamphetamine (MDMA)-induced neuroinflammation and dopamine neuron toxicity in mouse brain (2011) (0)
- Changes in GAD67 and peptides mRNA levels in specific populations of striatal efferent neurons following priming with dopamine agonists in 6-OHDA lesioned rats (2002) (0)
- Differential effect of priming with dopamine agonists on mrna for GAD-67, dynorphin and enkephalin in 6-OHDA lesioned rats (2000) (0)
- ALDH (2020) (0)
- Epival (1997) (0)
- PERIPHERAL, BUT NOT CENTRAL, INJECTIONS OF CCK-TETRAPEPTIDE INCREASE PANIC-LIKE BEHAVIOUR IN RATS (1996) (0)
- Possible biochemical mechanisms of the priming of dopamine receptor stimulated turning behavior (1990) (0)
- Sensitization to the motor stimulant effects of caffeine depends on the time from dopamine deneravation and on previous exposure to dopamine receptor agonists (1997) (0)
- Progression and Persistence of Neurotoxicity Induced by MDMA in Dopaminergic Regions of the Mouse Brain and Association with Noradrenergic, GABAergic, and Serotonergic Damage (2017) (0)
- Desvenlafaxine (2018) (0)
- SENSITIZATION TO THE MOTOR STIMULANT EFFECTS OF CAFFEINE IN 6‐HYDROXYDOPAMINE LESIONED RATS IS DEPENDENT ON DOPAMINE RECEPTORS (1998) (0)
- OPIOID MECHANISMS, AMPHETAMINE SENSITIZATION, AND ANIMAL MODELS OF INGESTIVE DISORDERS (1996) (0)
- Activation of adenosine A2A receptors suppresses the emission of pro-social and drug-stimulated 50-kHz ultrasonic vocalizations in rats: possible relevance to reward and motivation (2015) (0)
- ROLE OF EXCITATORY AMINO-ACIDS IN PARKINSONS-DISEASE AS STUDIED BY THE 6-OHDA MODEL OF PARKINSONISM IN RATS (1995) (0)
- Erratum to: MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex (2014) (0)
- COMPOUNDS INHIBITING THE ENZYME LACTATE DEHYDROGENASE (LDH), PHARMACEUTICAL COMPOSITIONS AND USES THEREOF (2013) (0)
- STIMULATION OF ADENOSINE A RECEPTORS BY CGS 21680 INDUCES FOS-LIKE IMMUNOREACTIVITY IN THE SHELL OF THE NUCLEUS ACCUMBENS: POSSIBLE ANTIPSYCHOTIC EFFECTS (1996) (0)
- Blockade of pallidal adenosine A2A receptors potentiates contralateral rotational behavior induced by L-DOPA and dopaminergic agonists in hemiparkinsonian rats (2007) (0)
- Synthesis of Substituted Carbamo(dithioperoxo)thioates as Potential BCA2-Inhibitory Anticancer Agents. (2015) (0)
- MODULATION OF TURNING BEHAVIOUR INDUCED BY DOPAMINE DI AND D2 AGONISTS IN 6-HYDROXYDOPAMINE-LESIONED RATS BY INTRANIGRAL INFUSION OF GLUTAMATE ANTAGONISTS (1996) (0)
- Chemical Therapeutics Novel Inhibitors of Rad 6 Ubiquitin Conjugating Enzyme : Design , Synthesis , Identi fi cation , and Functional Characterization (2013) (0)
- BLOCKADE OF ADENOSINE A2 RECEPTORS POSITIVELY MODULATES TURNING BEHAVIOUR AND C-FOS EXPRESSION INDUCED BY DI DOPAMINE AGONISTS IN DOPAMINE DENERVATED RATS (1996) (0)
- Objective diagnosis of drowning: the diatom test revisited through the use of atomic force microscopy. (2014) (0)
- LIMBIC CORTICAL INFLUENCES ON STIMULANT AND CONDITIONED REINFORCEMENT (1996) (0)
- INTERACTION BETWEEN NMDA RECEPTOR ANTAGONISTS AND DOPAMINERGIC AGONISTS IN THE 6-HYDROXYDOPAMINE MODEL OF PARKINSON: CLUES FOR THERAPY (1992) (0)
- Caffeine potentiates 3,4 methylenedioxymethamphetamine (MDMA, ecstasy)-induced-glial activation: role of age and adenosine A1 and A2A receptors (2010) (0)
- Novel Pyrazolopyrimidine Derivatives as Therapeutic Agents for the Treatment of Medullary Thyroid Carcinoma (2011) (0)
- Memoria: Fra Neurobiologia Identità Etica (2010) (0)
- [TEST OF ADRENAL CORTEX STIMULATION WITH SYNTHETIC ACTH (BETA 1-24-CORTICOTROPIN)]. (1963) (0)
- Changes in the Expression of Tonic and Phasic Neurochemical Markers of Activity in a Rat Model of L-DOPA Induced Dyskinesia (2005) (0)
- Potent cyclic enkephalin analogues for delta opioid receptors in the rat brain (1986) (0)
- Priming of the Behavioral Expression of Dopamine-Receptor Supersensitivity in the Basal Ganglia: Pharmacological and Biochemical Studies (1991) (0)
- Acute and long-term neuronal loss induced by perinatal asphyxia: activation of pro-apoptotic, anti-apoptotic and sentinel proteins (2009) (0)
- The Influence of Priming on the Behavioral Expression of Dopamine Receptor Supersensitivity in Basal Ganglia (1990) (0)
- Blockade ofNMDA receptors differentially affectsD-1 andD-2 mediated turning behavior in the 6-hydroxydopamine model of Parkinson (1991) (0)
- A2A adenosine receptor antagonists effet on hydroxyl radical generation in DA depleted striatum with reserpine (2009) (0)
- Different Patterns of Behavior and Gene Expression Induced by Chronic L-Dopa and A2A Antagonists Plus L-Dopa Treatments in 6- Hydroxydopamine Lesioned Rats (2002) (0)
- P14 SENSITISATION IN TURNING BEHAVIOUR AND ABNORMAL INVOLUNTARY MOVEMENTS IN 6-HYDROXYDOPAMINE LESIONED RATS: INFLUENCE OF THE ENVIRONMENT IN WHICH TESTS ARE PERFORMED. (2006) (0)
- S8 ADENOSINE A2A RECEPTOR ANTAGONISTS IN THE THERAPY OF PARKINSON??S DISEASE (2006) (0)
- Symptomatic efficacy of mucuna pruriens seed extract in rodent model of Parkinson's disease (2009) (0)
- ‘Priming’ Phenomena in the Expression of D1 and D2 Receptor Supersensitivity (1988) (0)
- 17 Rehabilitation improves dyskinesias in Parkinsonian patients: A pilot study comparing two different rehabilitative treatments (2012) (0)
- Preface [ to The Adenosinergic System. A Non-Dopaminergic Target in Parkinson’s Disease] (2015) (0)
- On the Role of Mesencephalic Reticular Formation and Superior Colliculus in the Expression of Dopaminergic Behavioural Syndromes (1982) (0)
- Metformin Prevented Dopaminergic Neurotoxicity Induced by 3,4-Methylenedioxymethamphetamine Administration (2016) (0)
- Books received (2005) (0)
- Adenosine A2A receptor antagonist treatment of Parkinson’s disease (2007) (0)
- Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease (2016) (0)
- 1303 – EXTRAPIRAMIDAL EFFECTS OF INTRA-THALAMIC INJECTION OF MUSCIMOL AND PICROTOXIN (1978) (0)
- Modulatory role of adenosine A(2A) receptors in basal ganglia as basis for the use of A(2A) antagonists in the treatment of Parkinson's disease (2006) (0)
- Optimized Synthesis of Diamino‐Triazinylmethyl Benzoates as Inhibitors of Rad6B Ubiquitin Conjugating Enzyme. (2015) (0)
- The Putative Neuroprotective Effects of Caffeine (2011) (0)
- The role of the dorsal mesencephalic reticular formation and deep layers of the superior colliculus in the turning behavior originating from the corpus striatum. (1982) (0)
- Abstract from the 2015 Neurotoxicity Society Meeting: Speaker Abstracts (2016) (0)
- Combined administration of an A2A receptor antagonist and a 5-HT1A/1B receptor agonist reverses neuroinflammation in the 6-OHDA model of Parkinson’s disease (2018) (0)
- A Critical Evaluation of Behavioral Rodent Models of Motor Impairment Used for Screening of Antiparkinsonian Activity: The Case of Adenosine A2A Receptor Antagonists (2013) (0)
- Behavioural and biochemical correlates of high and low dyskinetic parkinsonian drugs (2008) (0)
- ANTISENSE MEDIATED “KNOCKDOWN” OF STRIATAL DELTAFOSB EXPRESSION ATTENUATES PRIMING (1996) (0)
- Chronic intraventricular infusion of MPP+ with alzet osmotic minipumps in rats as a model of parkinson's disease (2009) (0)
- NCX1 and NCX3 as potential factors contributing to neurodegeneration and neuroinflammation in the A53T transgenic mouse model of Parkinson’s Disease (2018) (0)
- P10 INTERACTION BETWEEN METABOTROPIC ADENOSINE A2A - AND GLUTAMATE MGLU5 RECEPTORS IN PARKINSONIAN-LIKE MUSCLE RIGIDITY AND TREMOR (2006) (0)
- Differential interaction of dopaminergic D-1 and D-2 receptors with glutamatergic, gabaergic and cholinergic transmission in the 6-hyroxydopamine model of Parkinson (1992) (0)
- The GABA shift: A predictor of anxiolytic efficacy (1982) (0)
- Genetic deletion of Rhes increases susceptibility to the neuroinflammatory and dopaminergic neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) (2018) (0)
- A87 MODIFICATIONOFNALOXONE-INDUCEDWITHDRAWAL SIGNSBYASCORBICACID INMORPHINE-DEPENDENT GUINEA-PIGS D.Farzin,A.Arjmandand F.Aghabarari (2005) (0)
- Multi-target agents for the treatment of type II diabetic disorder: the new challenge in pharmacotherapy (2010) (0)
- EFFECTS OF ETHANOL ON TRANSCRIPTION OF ENZYMES INVOLVED IN GLUCOSE UPTAKE AND METABOLISM IN RAT BRAIN (1996) (0)
- Role of 3H-MPP+ binding sites in the MPTP neurotoxicity using quantitative autoradiography (1990) (0)
- Effect of caffeine on 3, 4 – methylenedioxymethamphetamine – induced astroglia and microglia activation in mouse brain (2009) (0)
- Behavioral and biochemical characterization as antiparkinsonian drug of the new adenosine A2A antagonist 8-ethoxy-9-ethyladenine (2010) (0)
- What is an animal model ? (2005) (0)
- A novel triazolopyridazine, [3H]CL 218,872 which labels the benzodiazepine receptor in rat brain (1982) (0)
- Emission of 50‑kHz ultrasonic vocalizations in dopamine-denervated rats treated with amphetamine: relevance to neurocircuitries involved in drug-mediated reward (2019) (0)
- Caffeine potentiation of 3,4-methylenedioxymethamphetamine (MDMA) toxicity: role of age (2011) (0)
- Serotonin 5-HT1A receptors and their interactions with adenosine A2A receptors in Parkinson's disease and dyskinesia (2023) (0)
- P5738Active fixation lead improves clinical response to cardiac resynchronisation therapy (2018) (0)
- Behavioural Correlates of Dopaminergic Agonists’ Dyskinetic Potential in the 6-OHDA-Lesioned Rat (2009) (0)
- Neurochemical and Neurotoxic Effects of MDMA (Ecstasy) and Caffeine After Chronic Combined Administration in Mice (2017) (0)
- P2.017 Behavioural and biochemical characterization of c-Rel mutant mice as model of Parkinson's disease (2009) (0)
- The Adenosinergic System (2015) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Micaela Morelli?
Micaela Morelli is affiliated with the following schools:
